within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01E_OtherCardiacPreparations.C01EB07_Fructose16Diphosphate;

model Fructose16Diphosphate
  extends Pharmacolibrary.Drugs.ATC.C.C01EB07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01EB07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fructose 1,6-diphosphate is a phosphorylated carbohydrate compound that has been investigated as a cardioprotective agent in experimental and limited clinical settings, particularly for myocardial ischemia or reperfusion injury. It is not currently an approved drug for routine clinical use.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies available. Parameters are estimated based on physicochemical properties, indirect preclinical reports, and analogous simple carbohydrates.</p><h4>References</h4><ol><li><p>Rigobello, MP, &amp; Galzigna, L (1982). Pharmacokinetics of fructose-1, 6-diphosphate in the rat. <i>Il Farmaco; edizione scientifica</i> 37(7) 459–462. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7128804/\">https://pubmed.ncbi.nlm.nih.gov/7128804</a></p></li><li><p>De Bernardis, E, et al., &amp; Rizza, V (1988). [Effects of fructose-1,6-diphosphate on blood concentration of alcohol in man]. <i>Recenti progressi in medicina</i> 79(5) 220–223. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3175275/\">https://pubmed.ncbi.nlm.nih.gov/3175275</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fructose16Diphosphate;
